Etofylline + Theophylline Tablet Franchise in Ahmedabad

Bronchodilator Tablet Supplier in Bangalore

Respiratory Therapy Tablet Distributor in Hyderabad

Asthma & COPD Tablet Franchise Opportunity in Jaipur

Pulmonary Care Tablet Stockist in Mumbai
Etofylline + Theophylline Tablet Export & Manufacturing in Chandigarh

Home/Products /etofylline-231mg-theophylline-69mg-tablet

Etohype 300 Tablet

Composition : Etofylline (231mg) + Theophylline (69mg) Tablet

Dosage Form : Tablet

Packaging Type : Alu Alu

Packaging : 10*15

Price : ₹1/-

Etohype 300 Tablet contains Etofylline 231mg + Theophylline 69mg, a potent bronchodilator combination widely used for managing asthma, chronic obstructive pulmonary disease (COPD), and other obstructive airway disorders. It relaxes bronchial smooth muscles, improving airflow and easing breathing difficulties.

The formulation provides sustained therapeutic action, making it suitable for maintenance therapy and long-term management of chronic respiratory conditions. Its convenient oral form ensures ease of use for adult patients.

For hospitals, respiratory clinics, and distributors, Etohype 300 Tablet is a high-demand respiratory-care product, regularly prescribed in pulmonary wards, outpatient respiratory departments, and critical-care units. Continuous use ensures stable demand and repeat orders.

Adding Etohype 300 Tablet to your portfolio strengthens your respiratory and pulmonary therapy segment, creating opportunities in hospital supply chains, pharmacy distribution, institutional orders, export markets, and third-party manufacturing. Its clinical efficacy and widespread prescription make it a valuable and profitable addition for pharmaceutical distributors.

Read More

About the Product

Etohype 300 Tablet contains Etofylline 231mg + Theophylline 69mg, a potent bronchodilator combination widely used for managing asthma, chronic obstructive pulmonary disease (COPD), and other obstructive airway disorders. It relaxes bronchial smooth muscles, improving airflow and easing breathing difficulties.

The formulation provides sustained therapeutic action, making it suitable for maintenance therapy and long-term management of chronic respiratory conditions. Its convenient oral form ensures ease of use for adult patients.

For hospitals, respiratory clinics, and distributors, Etohype 300 Tablet is a high-demand respiratory-care product, regularly prescribed in pulmonary wards, outpatient respiratory departments, and critical-care units. Continuous use ensures stable demand and repeat orders.

Adding Etohype 300 Tablet to your portfolio strengthens your respiratory and pulmonary therapy segment, creating opportunities in hospital supply chains, pharmacy distribution, institutional orders, export markets, and third-party manufacturing. Its clinical efficacy and widespread prescription make it a valuable and profitable addition for pharmaceutical distributors.

Some patients may experience nausea, vomiting, headache, palpitations, dizziness, or mild insomnia. Rarely, arrhythmias, allergic reactions, or gastrointestinal disturbances may occur.

Etohype 300 Tablet is indicated for the management of bronchial asthma, chronic obstructive pulmonary disease (COPD), and other conditions associated with bronchospasm. It helps relieve symptoms such as wheezing, shortness of breath, and chest tightness.

Use strictly under medical supervision. Monitor heart rate and blood pressure during therapy. Avoid in patients with hypersensitivity to xanthine derivatives, cardiac arrhythmias, or severe liver disease. Take the tablet as prescribed.

Store in a cool, dry place below 25°C, protected from light and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation